Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell Lymphoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

20 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-03-01

Study Completion Date

2027-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a prospective cohort study. The case group will include patients with primary central nervous system lymphoma confirmed by imaging and pathology. The control group will include patients with pathologically confirmed diffuse large B-cell lymphoma who have been excluded from central nervous system involvement, as well as age- and gender-matched healthy volunteers (hematopoietic stem cell donors). Baseline data (as described below) will be collected. Patients with primary CNS lymphoma will undergo follow-up every 3 months, with immediate follow-up if clinical symptoms arise.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Use of Biomarkers to Predict CNS Involvement in Diffuse Large B-Cell Lymphoma: a Danish Nationwide Registry Study

NCT05169203

Diffuse Large B Cell Lymphoma Diffuse Large B-Cell Lymphoma Cell of Origin Diffuse Large B-cell Lymphoma Recurrent

COMPLETED

Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach

NCT07147751

Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL)

NOT_YET_RECRUITING

Study of the Pronostic Impact of Immunohistochemical, Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma.

NCT05347511

Rare Disease With Poor Outcome

UNKNOWN

Prospective Cohort Study With Central Nervous System Evaluation in Diffuse Large B-cell Lymphoma

NCT01202448

Diffuse Large B-cell Lymphoma

COMPLETED NA

Characterisation of TIM-3/Gal-9 Immune Checkpoints in Primary Central Nervous System Diffuse Large B Cell Lymphomas

NCT05133505

Lymphoma, B-Cell

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Central Nervous System Lymphoma (PCNSL) Diffuse Large B-Cell Lymphoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PCNSL

Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System

No interventions assigned to this group

GDLBCL

Diffuse large B-cell lymphoma of the gastrointestinal tract

No interventions assigned to this group

DLBCL

Non-Hodgkin's diffuse large B-cell lymphoma not involving the central nervous system or gastrointestinal tract

No interventions assigned to this group

Health

Healthy control

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Aged between 18 and 75 years.
2. The case group must have a confirmed diagnosis of primary central nervous system lymphoma (PCNSL) and must not have received any antitumor therapy prior to baseline sample collection.
3. Must sign an informed consent form, agree to participate in this study, and provide samples and clinical information as required.
4. Case group patients must have complete supporting imaging and pathology data.

Exclusion Criteria

1. Presence of other systemic malignancies.
2. Presence of severe infections or metabolic disorders.
3. Use of antimetabolites or chemotherapy drugs within one week prior to sample collection.
4. Pregnant or lactating women.
5. Concurrent severe internal medical conditions (e.g., end-stage renal disease, heart failure, liver failure).
6. Patients unable to complete study requirements due to psychiatric disorders or cognitive impairment.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes